For example, the poly(ADP-ribose) polymerase inhibitor olaparib leads to an improvement in progression-free survival of ~3 years in patients with BRCA1/2-altered ovarian tumors [32], compared with up to ~7 months for BRCA1/2-altered breast, pancreatic, or prostate cancer [33,34,35]. This evidence concerns the gene BRCA1 and prostate carcinoma.